Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma

Cancer Science

Volumn 101, Issue 1, 2010, Pages 46-53

  Kuroda, Koji ^a   Takenoyama, Mitsuhiro ^a   Baba, Tetsuro ^a   Shigematsu, Yoshiki ^a   Shiota, Hironobu ^a   Ichiki, Yoshinobu ^a   Yasuda, Manabu ^a   Uramoto, Hidetaka ^a   Hanagiri, Takeshi ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; CYCLIN D3; GAMMA INTERFERON; RIBOSOME PROTEIN; RIBOSOME PROTEIN L19; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME REPRESSION; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; FEMALE; HLA-A ANTIGENS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; RIBOSOMAL PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 71849090958     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01351.x     Document Type: Article

References (48)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. van der Bruggen P, Traversari C, Chomez P. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-7.
4. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997, 18:267-8.
5. Van den Eynde BJ, van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-93.
6. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001, 61:5544-51.
7. Rosenberg SA, Yang JC, Schwartzentruber DJ. Immunologic and therapeutic evaluation of a s ynthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-7.
8. Godelaine D, Carrasco J, Lucas S. Polyclonal CTL responses observed in melanoma patients vacci-nated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 2003, 171:4893-7.
9. Coulie PG, Karanikas V, Colau D. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor associated antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001, 98:10290-5.
10. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-15.
11. Sugaya M, Takenoyama M, Osaki T. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002, 122:282-8.
12. Takenoyama M, Yoshino I, Eifuku R. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 2001, 92:309-15.
13. Takenoyama M, Yoshino I, Fujie H. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res 1998, 89:60-6.
14. So T, Takenoyama M, Ichiki Y. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer 2005, 103:200-8.
15. Ichiki Y, Takenoyama M, Mizukami M. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004, 172:4844-50.
16. Nagata Y, Hanagiri T, Takenoyama M. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005, 11:5265-72.
17. Takenoyama M, Baurain JF, Yasuda M. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006, 118:1992-7.
18. Fukuyama T, Hanagiri T, Takenoyama M. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 2006, 66:4922-8.
19. Sugaya M, Takenoyama M, Shigematsu Y. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 2006, 120:1055-62.
20. So T, Takenoyama M, Mizukami M. Haplotype loss of HLA-class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005, 65:5945-52.
21. Baba T, Hanagiri T, Ichiki Y. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leucocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007, 98:1795-802.
22. Misawa K, Nosaka T, Morita S. A method to identify cDNAs based on localization of green fluorescent protein fusion products. Proc Natl Acad Sci U S A 2000, 97:3062-6.
23. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocy tes. J Immunol Methods 1986, 95:99-105.
24. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989, 119:203-10.
25. Slingluff CL, Cox AL, Stover JM, Moore MM, Hunt DF, Engelhard VH. Cy totoxi c T-l ymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994, 54:2731-7.
26. Echchakir H, Mami-Chouaib F, Vergnon I. A point mutation in the a-actinin-4 gene generates an antigenic peptide recognized by autologous cytolyticT lymphocytes on a human lung carcinoma. Cancer Res 2001, 61:4078-83.
27. Maguire BA, Zimmermann RA. The ribosome in focus. Cell 2001, 104:813-6.
28. Ramakrishnan V. Ribosome structure and the mech-anism of translation. Cell 2002, 108:557-72.
29. Davies B, Fried M. The L19 ribosomal protein gene (RPL19): gene organization, chromosomal mapping, and novel promoter region. Genomics 1995, 25:372-80.
30. Kumabe T, Sohgma Y, Yamamoto T. Human cDNAs encoding elongation factor 1gamma and the ribosomal protein L19. Nucleic Acids Res 1992, 20:2598.
31. Bee A, Ke Y, Forootan S. Ribosomal protein L19 is a prognostic marker for human prostate cancer. Clin Cancer Res 2006, 12:2061-5.
32. Huang CJ, Chien CC, Yang SH. Fecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med 2008, 12:1936-43.
33. Henry JL, Coggin DL, King CR. High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. Cancer Res 1993, 53:1403-8.
34. Yoshino I, Goedegebuure PS, Peoples GE. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994, 54:3387-90.
35. Lane DP. p53 and human cancers. Br Med Bull 2000, 50:582.
36. Röpke M, Hald J, Guldberg P. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996, 93:14704-7.
37. Eura M, Chikamatsu K, Katsura F. A wild type sequence p53 peptide presented by HLA-A24 induced cytotoxic T lymphocyte that recognize squamous cell carcinoma of the head and neck. Clin Cancer Res 2000, 6:979-86.
38. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild type p53 epitope presented by breast carcinoma and melanomas. J Immunol 1998, 160:328.
39. Bakker AB, Schreurs MW, de Boer AJ. Melanocyte Lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994, 179:1005-9.
40. Ciernik IF, Berzofsky JA, Carbone DP. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and lysed by mutant -specific cytotoxic T lymphocytes. Clin Cancer Res 1996, 2:877-82.
41. Kawakami Y, Eliyahu S, Sakaguchi K. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180:347-52.
42. Kawakami Y, Eliyahu S, Delgado CH. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994, 91:6458-62.
43. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-12.
44. Diehl JA, Zindy F, sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997, 11:957-72.
45. Shin I, Yakes FM, Rojo F. PKB/AKt mediates cell-cycle progression by phosphorylation of p27kip1 at threonine 157 and modulation of its cellular localization. Nat med 2002, 8:1145-52.
46. Vansteenkiste J, Zielinski M, Linder A. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol Suppl 2007, 25.
47. Takedatsu H, Shichijo S, Azuma K, Takedatsu H, Sata M, Itoh K. Detection of a set of peptide vaccine candidates for use in HLA-A31+ epitherial cancer patients. Int J Oncol 2004, 24:337-47.
48. Hashimoto M, Kinoshita T, Yamasaki M. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 1994, 44:166-73.